Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term

Qiagen (QGEN) is highlighted as a compelling growth stock, holding a Zacks Rank #2 (Buy) and a VGM Score of A. The company's growth prospects are supported by a Growth Style Score of B, with a projected 6.9% year-over-year earnings growth for the current fiscal year and a 4.9% average earnings surprise. Furthermore, eight analysts have increased their fiscal 2025 earnings estimates in the last 60 days, raising the Zacks Consensus Estimate to $2.33 per share.

Analysis

Qiagen (QGEN) presents a compelling investment case, primarily driven by its strong growth indicators and positive analyst sentiment, as reflected by its Zacks Rank #2 (Buy) and a top-tier VGM Score of A. The company, a leading provider of technologies for nucleic acid handling and molecular diagnostics, also secures a Growth Style Score of B, underpinned by a forecasted year-over-year earnings growth of 6.9% for the current fiscal year. This growth outlook is further substantiated by a consistent history of positive earnings surprises, averaging 4.9%. Notably, eight analysts have revised their earnings estimates upward for fiscal 2025 within the past 60 days, elevating the Zacks Consensus Estimate by $0.07 to $2.33 per share. These metrics, combined with Qiagen's extensive portfolio of over 500 proprietary products, suggest a robust operational footing and favorable market positioning. The overall sentiment for the company is strongly positive, with a specific sentiment score of 0.9 for QGEN, indicating strong market optimism.

Key Decisions for Investors

• Investors seeking growth opportunities should consider Qiagen (QGEN) due to its favorable Zacks Rank #2 (Buy), strong VGM and Growth Style Scores, and positive earnings outlook highlighted by a 6.9% projected YoY earnings growth.
• The upward revision of fiscal 2025 earnings estimates by eight analysts, resulting in a consensus of $2.33 per share, and a consistent 4.9% average earnings surprise, signal strengthening fundamentals and potential for share price appreciation.
• Given the company's position in nucleic acid technologies and molecular diagnostics, continued monitoring of product innovation, market adoption, and analyst sentiment will be crucial for assessing long-term value.